Comments on: Avastin May Have Role in Early Breast Cancer Treatment http://s389932830.onlinehome.us/blog/2012/02/avastin-early-treatment/ Just another WordPress site Wed, 11 Jul 2012 18:01:36 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: Gregory Pawelski http://s389932830.onlinehome.us/blog/2012/02/avastin-early-treatment/#comment-2067 Gregory Pawelski Fri, 17 Feb 2012 16:21:00 +0000 https://www.pabreastcancer.org/blog/?p=2057#comment-2067 Avastin is thought to work by blocking the formation of blood vessels (angiogenesis) that feed tumors. This is what is actually measured with the AngioRx assay, which simultaneously measures direct anti-tumor and anti-vascular activity within the three dimensional (3D) tumor cell clusters. The test is capable of discriminating anti-tumor effect from anti-angiogenic effect in the same mixed-cell population. Within 24 hours of VEGF inhibition, endothelial cells have been shown to shrivel, retract, fragment and die by apoptosis. It is the only known technology which discriminates the effects of different types of anti-angiogenic drugs within the same class of drugs and within different classes of drugs, and is capable of identifying synergistic effects among different angiogenic and non-angiogenic drugs in specific drug combinations. And there are a number of new classes of drugs that target VEGF, at the protein level (Avastin), at the tyrosine kinase level (Nexavar, Sutent) and at the intracellular metabolic pathway mTOR (Afinitor, Torisel). Without a marker that identifies those most likely to benefit, you're just treating everybody, and the subgroup that gets the benefit gets diluted out. Biologic therapy is on the ascendancy. The possibility of eradicating cancer by selective destructon of tumor blood vessels may represent an attractive therapeutic avenue. It's going to take combination antivascular therapy to make a difference. The AngioRx assay is the most promising technology on the therapeutic horizon. And, on top of that, you can put a vascular disrupting agent in combination with an antiangiogenesis agent. Avastin is thought to work by blocking the formation of blood vessels (angiogenesis) that feed tumors. This is what is actually measured with the AngioRx assay, which simultaneously measures direct anti-tumor and anti-vascular activity within the three dimensional (3D) tumor cell clusters. The test is capable of discriminating anti-tumor effect from anti-angiogenic effect in the same mixed-cell population. Within 24 hours of VEGF inhibition, endothelial cells have been shown to shrivel, retract, fragment and die by apoptosis.

It is the only known technology which discriminates the effects of different types of anti-angiogenic drugs within the same class of drugs and within different classes of drugs, and is capable of identifying synergistic effects among different angiogenic and non-angiogenic drugs in specific drug combinations. And there are a number of new classes of drugs that target VEGF, at the protein level (Avastin), at the tyrosine kinase level (Nexavar, Sutent) and at the intracellular metabolic pathway mTOR (Afinitor, Torisel).

Without a marker that identifies those most likely to benefit, you’re just treating everybody, and the subgroup that gets the benefit gets diluted out. Biologic therapy is on the ascendancy. The possibility of eradicating cancer by selective destructon of tumor blood vessels may represent an attractive therapeutic avenue. It’s going to take combination antivascular therapy to make a difference. The AngioRx assay is the most promising technology on the therapeutic horizon. And, on top of that, you can put a vascular disrupting agent in combination with an antiangiogenesis agent.

]]> By: Gregory Pawelski http://s389932830.onlinehome.us/blog/2012/02/avastin-early-treatment/#comment-86 Gregory Pawelski Fri, 17 Feb 2012 16:21:00 +0000 https://www.pabreastcancer.org/blog/?p=2057#comment-86 Avastin is thought to work by blocking the formation of blood vessels (angiogenesis) that feed tumors. This is what is actually measured with the AngioRx assay, which simultaneously measures direct anti-tumor and anti-vascular activity within the three dimensional (3D) tumor cell clusters. The test is capable of discriminating anti-tumor effect from anti-angiogenic effect in the same mixed-cell population. Within 24 hours of VEGF inhibition, endothelial cells have been shown to shrivel, retract, fragment and die by apoptosis. It is the only known technology which discriminates the effects of different types of anti-angiogenic drugs within the same class of drugs and within different classes of drugs, and is capable of identifying synergistic effects among different angiogenic and non-angiogenic drugs in specific drug combinations. And there are a number of new classes of drugs that target VEGF, at the protein level (Avastin), at the tyrosine kinase level (Nexavar, Sutent) and at the intracellular metabolic pathway mTOR (Afinitor, Torisel). Without a marker that identifies those most likely to benefit, you're just treating everybody, and the subgroup that gets the benefit gets diluted out. Biologic therapy is on the ascendancy. The possibility of eradicating cancer by selective destructon of tumor blood vessels may represent an attractive therapeutic avenue. It's going to take combination antivascular therapy to make a difference. The AngioRx assay is the most promising technology on the therapeutic horizon. And, on top of that, you can put a vascular disrupting agent in combination with an antiangiogenesis agent. Avastin is thought to work by blocking the formation of blood vessels (angiogenesis) that feed tumors. This is what is actually measured with the AngioRx assay, which simultaneously measures direct anti-tumor and anti-vascular activity within the three dimensional (3D) tumor cell clusters. The test is capable of discriminating anti-tumor effect from anti-angiogenic effect in the same mixed-cell population. Within 24 hours of VEGF inhibition, endothelial cells have been shown to shrivel, retract, fragment and die by apoptosis.

It is the only known technology which discriminates the effects of different types of anti-angiogenic drugs within the same class of drugs and within different classes of drugs, and is capable of identifying synergistic effects among different angiogenic and non-angiogenic drugs in specific drug combinations. And there are a number of new classes of drugs that target VEGF, at the protein level (Avastin), at the tyrosine kinase level (Nexavar, Sutent) and at the intracellular metabolic pathway mTOR (Afinitor, Torisel).

Without a marker that identifies those most likely to benefit, you’re just treating everybody, and the subgroup that gets the benefit gets diluted out. Biologic therapy is on the ascendancy. The possibility of eradicating cancer by selective destructon of tumor blood vessels may represent an attractive therapeutic avenue. It’s going to take combination antivascular therapy to make a difference. The AngioRx assay is the most promising technology on the therapeutic horizon. And, on top of that, you can put a vascular disrupting agent in combination with an antiangiogenesis agent.

]]> By: Cheryl http://s389932830.onlinehome.us/blog/2012/02/avastin-early-treatment/#comment-2066 Cheryl Fri, 17 Feb 2012 14:53:00 +0000 https://www.pabreastcancer.org/blog/?p=2057#comment-2066 I was so proud to be part of that study. At diagnosis I had a 2cm+ with fingerlings, grade three tumor, trip. negative. The day of y second round of chemo with Avastin the tumor was no longer palpable by my oncologist. I was so proud to be part of that study. At diagnosis I had a 2cm+ with fingerlings, grade three tumor, trip. negative. The day of y second round of chemo with Avastin the tumor was no longer palpable by my oncologist.

]]> By: Cheryl http://s389932830.onlinehome.us/blog/2012/02/avastin-early-treatment/#comment-85 Cheryl Fri, 17 Feb 2012 14:53:00 +0000 https://www.pabreastcancer.org/blog/?p=2057#comment-85 I was so proud to be part of that study. At diagnosis I had a 2cm+ with fingerlings, grade three tumor, trip. negative. The day of y second round of chemo with Avastin the tumor was no longer palpable by my oncologist. I was so proud to be part of that study. At diagnosis I had a 2cm+ with fingerlings, grade three tumor, trip. negative. The day of y second round of chemo with Avastin the tumor was no longer palpable by my oncologist.

]]>